Arkema (AKE) BNPP Exane CEO Conference Presentation summary
Event summary combining transcript, slides, and related documents.
BNPP Exane CEO Conference Presentation summary
13 Jan, 2026Business overview and market positioning
Generated €9.5bn in 2023 sales, with 92% from specialty materials across 151 production sites in 55 countries.
Key markets include building & construction, general industry, consumer goods & electronics, water, health & nutrition, and transportation & energy.
North America, Europe, and Asia represent the largest sales regions, with 37%, 34%, and 24% of sales, respectively.
Focused on three specialty materials segments: Adhesive Solutions, Coating Solutions, and Advanced Materials.
Financial performance and capital management
2023 sales reached €9.5bn with an EBITDA of €1,457m and a margin of 15.8%.
Recurring cash flow in 2023 was €761m, with a 50.7% EBITDA to cash conversion rate, exceeding the 40% target.
Debt successfully refinanced in 2023 and early 2024, maintaining a solid investment grade rating (Baa1/BBB+).
Dividend has grown at a 12% average annual rate from 2019 to 2023, with a 40% payout ratio for 2023.
Strategic vision and growth ambitions
Aims to be a specialty materials leader, offering innovative and sustainable solutions.
Targets €12bn sales and ~18% EBITDA margin by 2028, with organic sales CAGR of 4% and EBITDA CAGR of 7-8% (2024-28).
Each segment has set aligned growth and margin targets, with Advanced Materials aiming for 6% annual sales growth.
EBITDA growth driven by major capex in growth markets and ongoing organic growth, targeting €10bn cumulative EBITDA (2024-28).
Capital allocation prioritizes maintenance, growth capex, M&A, and shareholder returns, with ~€7bn operating cash flow expected (2024-28).
Latest events from Arkema
- EBITDA dropped but cash flow and cost savings were strong, with Asia and growth markets outperforming.AKE
Q4 202526 Feb 2026 - Q2 2024 EBITDA rose 8.2% on 3.8% sales growth, with guidance raised for the year.AKE
Q2 20242 Feb 2026 - Q3 2024 EBITDA rose 5.4% to €407 million, margin at 17.0%, amid weak demand and tight debt control.AKE
Q3 202416 Jan 2026 - Q3 2024 saw higher sales and EBITDA, with strong specialty materials growth and sustainability focus.AKE
BOFA European Materials Conference 2024 Presentation13 Jan 2026 - Solid Q2 growth and sustainability focus drive higher 2024 EBITDA outlook of €1.53–1.63bn.AKE
Investor presentation13 Jan 2026 - Strong specialty materials growth, resilient margins, and major investments drive future expansion.AKE
Morgan Stanley Chemicals Cannonball Run Field Trip Presentation13 Jan 2026 - EBITDA margin held at 15.2% in Q2 2025, with cost-saving targets doubled for the year.AKE
Q2 202513 Jan 2026 - 2024 EBITDA rose 2.1% to €1.53bn, led by Specialty Materials and Asian growth.AKE
Q4 202418 Dec 2025 - Sales growth in Asia offset weak Western demand, but profits fell; 2025 outlook stable.AKE
Q1 202518 Nov 2025